- Microdosing psilocybin can improve the quality of creative thinking by helping people come up with more original ideas.
- The practice does not appear to help with “convergent thinking,” which is the ability to find a single correct answer to a problem.
- The effects are subtle and can be influenced by a person’s body weight and their previous experience with psychedelics.
Summary of Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
Introduction
Creativity is a complex process that involves two different types of thinking. The first is convergent thinking, which is the ability to find the single correct solution to a problem. The second is divergent thinking, which involves generating a wide variety of different, loosely associated ideas. While large doses of psychedelics are known to change how people perceive the world and link concepts together, researchers wanted to know if much smaller, repeated doses might offer a similar boost to these creative processes.
Previous research in this area has often been limited by small group sizes or “open-label” surveys where participants knew whether they were taking a drug or a placebo. This research aimed to address those gaps by conducting three strictly controlled, double-blind experiments. The goal was to see if microdosing psilocybin could specifically enhance different aspects of creative cognition by affecting the brain’s ability to be flexible and make new associations.
Methods
Three separate trials were conducted in the Netherlands using magic truffles, which contain the psychedelic compound psilocybin. Participants took their doses approximately every three days in their own homes, following a set schedule. To ensure the results were reliable, an external organization handled the randomization using opaque capsules so that neither the participants nor the researchers knew who was receiving the active dose and who was receiving a placebo.
Experimental Design
The first experiment used a low dose of about 0.65 grams of fresh truffles and compared different groups of participants to see how they performed on creativity tasks. The second experiment increased the dose to approximately 1 gram and lasted for about four weeks, helping researchers see if a slightly higher dose or longer duration changed the outcome.
The third experiment used a higher dose of about 1.5 grams and employed a “crossover” design. In this version, every participant tried both the microdose and a placebo at different times, allowing researchers to compare how the same individual performed under both conditions. Finally, a “mega-analysis” was performed by pooling the data from all three trials to increase the statistical power of the findings, looking at a total of approximately 169 to 171 participants.
Results
Blinding was successful across the trials, meaning most participants could not correctly guess whether they were in the active or placebo group. However, a notable trend emerged regarding experience: people who had used psychedelics in the past were more likely to report feeling effects even when they were actually taking a placebo. This suggests that prior experience can play a significant role in how someone perceives the impact of a microdose.
Impact on Creative Quality
When the data from all three experiments were combined, a clear pattern emerged regarding the quality of ideas. While microdosing did not increase “fluency”—the total number of ideas a person could come up with—it did significantly increase the “originality ratio.” This means that while people weren’t coming up with more ideas in total, a much higher percentage of the ideas they did produce were unique and original.
In the first experiment, the increase in originality was quite strong, with an effect size of 0.84. In the third experiment, the originality ratio under microdosing was 0.316, compared to only 0.100 for the placebo group. The combined analysis confirmed this, showing significant evidence that microdosing helps the quality of divergent thinking (p = 0.002).
Non-Significant Findings
Microdosing did not appear to help with convergent thinking, which is the ability to find a specific, correct answer. Additionally, the studies found no reliable evidence that microdosing increases the sheer volume of ideas produced. The effect is highly specific to the uniqueness of the thoughts rather than the quantity or the ability to solve standard puzzles.
Weight also appeared to be a factor in how the dose worked. Regression analysis showed that the amount of psilocybin relative to a person’s body weight predicted how original their ideas were. This suggests that heavier individuals may require a higher absolute dose to experience the same boost in originality as lighter individuals.
Discussion
The findings suggest that psilocybin microdosing may act as a selective enhancer for creative thought. Rather than making the brain work faster, it may increase “cognitive flexibility.” This allows the mind to search through wider mental connections to find unusual associations, leading to more original answers during divergent thinking tasks.
There are several important nuances to these results. The high level of placebo responsiveness among experienced users means that personal expectations can heavily influence the perceived effects. Furthermore, because the doses were self-administered in natural settings, there were limitations in controlling the exact timing of the dose and the precise concentration of active ingredients in each truffle.
Conclusion
Microdosing psilocybin does not provide a universal boost to all types of intelligence or creativity. Instead, it seems to specifically enhance the originality of divergent ideas. The effect is subtle and is closely tied to the individual’s body weight and their previous history with psychedelic substances.
Because the results showed some variability across the different experiments, more research is needed. Future studies should focus on larger groups and include “naïve” participants—those with no prior experience using psychedelics—to confirm if these creative benefits are truly caused by the psilocybin or by the participants’ expectations. See also our coverage of Multimodal creativity assessments following acute, and our explainers on LSD and microdosing protocol. Read the full paper summary on Blossom.
